Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

References

• Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-48
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Casquero P, Villoslada P, Montalban X, et al. Frequency of multiple sclerosis in Menorca, Balearic Islands, Spain. Neuroepidemiology 2001;20:129-33
   PubMed Web of Science ®Google Scholar
• Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Arago´ n, Spain. J Neurol Sci 2003;216:89-93
   PubMed Web of Science ®Google Scholar
• Aladro Y, Alemany MJ, Perez-Vieitez MC, et al. Prevalence and incidence of multiple sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology 2005;24:70-5
   PubMed Web of Science ®Google Scholar
• Ares B, Prieto JM, Lema M, et al. Prevalence of multiple sclerosis in Santiago de Compostela (Galicia, Spain). Mult Scler 2007;13:262-4
   PubMedGoogle Scholar
• Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manage Care Pharm 2009;15:543-55
   PubMed Web of Science ®Google Scholar
• García Merino A, Fernández O, Montalbán X, et al. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy]. Neurologia 2010;25:378-90
   PubMed Web of Science ®Google Scholar
• Weiner HL, Hohol MJ, Khoury SJ, et al. Therapy for multiple sclerosis. Neurol Clin 1995;13:173-96
   PubMed Web of Science ®Google Scholar
• Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet 1998;352:1486-7
   PubMed Web of Science ®Google Scholar
• Gubieras L, Casado V, Romero-Pinel L, et al. Cost of the relapse of multiple sclerosis in Spain. Value Health 2011;14:233-510
   Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006;7:65-74
   PubMedGoogle Scholar
• Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. The costs of a multiple sclerosis relapse in Catalonia (Spain)]. Neurología 2006;21:341-7
   PubMed Web of Science ®Google Scholar
• Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4:1-101
   Google Scholar
• Lublin FD, Stacey S, Cofield SS, et al; Wolinsky JS, for the CombiRx Investigators; Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:1-14
   Google Scholar
• Yamamoto D, Campbell JD. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature. Autoimmune Dis Hindawi Publishing Corporation 2012;2012:1-13
   Google Scholar
• Sánchez-de la Rosa R, Sabater E, Casado MA, et al. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients. J Med Econ 2012;15:424-33
   PubMedGoogle Scholar
• Lublin FD, Cofield SS, Gustafson T, et al; Cutter GR for the The CombiRx Investigators Investigators. Assessment of relapse activity in the CombiRx Randomised Clinical Trial. 28th Congress of the European Committee for treatment and research in Multiple Sclerosis, 10-13 October 2012, Lyon, France. http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=157254&XNSPRACHE_ID=2&XNKONGRESS_ID=171&XNMASKEN_ID=900. Last accessed 25 October 2013
   Google Scholar
• Lindsey J, Scott T, Lynch S, et al; the CombiRx Investigators Group. The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: design and baseline characteristics. Mult Scler Relat Disord 2012;1:81-6
   Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos. BOT plus web. 2013. https://botplusweb.portalfarma.com/. Last accessed 25 October 2013
   Google Scholar
• Real Decreto-Ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit publico. Boletín Oficial del Estado (BOE), Madrid, 24 May 2010, no 126. Sec. I, p. 45070-128 http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Last accessed 25 October 2013
   Google Scholar
• Sánchez-De la Rosa R, Sabater E, Casado MA. Análisis del impacto presupuestario del tratamiento en primera línea de la esclerosis múltiple remitente recurrente en España. Rev Neurol 2011;53:129-38
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17
   PubMed Web of Science ®Google Scholar
• Pinto JL, Sanchez F. Métodos para la evaluación económica de nuevas prestaciones. Editado por: Centre de Recerca en Economía i Salut – Cres y Ministerio de Sanidad y Consumo, España. http://www.msc.es. Accessed April 10, 2013
   Google Scholar
• Castelli-Haley J, Oleen-Burkey MA, Lage MJ, et al. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis. Adv Ther 2009;26:552-62
   PubMed Web of Science ®Google Scholar
• Becker RV, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. J Manage Care Pharm 2011;17:377-81
   PubMed Web of Science ®Google Scholar
• Lublin F, Cofield S, Cutter G, et al. Relapse activity in the CombiRx Trial: blinded, 7-year extension results. Neurology 2013;80:(Meeting Abstracts) Poster number S01-002
   Google Scholar
• Lublin F, Cofield S, Cutter G, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Neurology 2013;80(Meeting Abstracts 1): Poster number Poster number P04.121
   Google Scholar
• Wolinsky J, Salter A, Narayana P, et al. MRI Outcomes in CombiRx: blinded, 7-year extension results. Neurology 2013;80(Meeting Abstracts 1): Poster number S01.003
   Google Scholar
• Arroyo E, Grau C, Ramo-Tello C, et al; GAP Study Group. Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project. Eur Neurol 2011;65:59-67
   PubMed Web of Science ®Google Scholar
• Arroyo E, Grau C, Ramo C, et al; por el grupo espanol del estudio GAP. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results]. Neurologia 2010;25:435-42
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics Avonex. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf. Last accessed 25 October 2013
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Ficha Técnica Copaxone. http://www.aemps.gob.es/cima/especialidad.do?metodo=verPresentaciones&codigo=65983. Last accessed 25 October 2013
   Google Scholar
• Menzin J, Caon C, Nichols C, et al. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 2013;19(1 Suppl):S24-40
   Web of Science ®Google Scholar
• Brandes DW, Raimundo K, Agashivala N, et al. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis. J Med Econ 2013;16:547-51
   PubMedGoogle Scholar
• Chilcott J, McCabe C, Tappenden P, et al; Claxton K on behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522
   PubMed Web of Science ®Google Scholar